Max-Delbrueck-Centrum Fuer Molekulare Medizin

The University of Texas System

Fresenius Medical Care Deutschland Gmbh

Charite - Universitaetsmedizin Berlin

Mdc Max-Delbruck-Centrum Fur Molekulare Medizin Berlin-Buch

Other

Max-Delbruck-Centrum Fur Molekulare Medizin

Fresenius Medical Care Affina Gmbh

Max-Delbrueck-Centrum Fuer Molekulare Medizin (Mdc)

Max-Delbrueck-Centrum Fuer Molkulare Medizin

Charite—universtatsmedizin Berlin

Max-Delbruck-Centrum Fur Molekular Medizin

Charité – Universitätsmedizin Berlin

Berlin Cures Gmbh

Gerd Wallukat

John Russell Falck

Robert Fischer

Wolf-Hagen Schunck

Dominik N Mueller

Rudolf Kunze

Annekathrin Haberland

Narender Puli

Ingolf Schimke

Cosima Arnold

Peter Rosenthal

Richard Straube

Anne Konkel

Thomas Harrer

Wolfgang Rönspeck

Johannes Müller

Claudia Dahmen

Dominik Müller

Manuela Dierenfeld

Peter Göttel

Reinhard Voll

Martin Herrmann

Friedrich Luft

Volker Homuth

Andreas Kage

Dominik Muller

Johannes Muller

Nareuder Puli

Cosima Schmidt

Peter Gottel

John R Falck

Anselm JÜNEMANN

Dominik N MÜLLER

Ursula Schlötzer

The present invention provides compounds (n-3 PUFA derivatives) of formula (I): that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.

Eicosanoid derivatives

The present invention relates to compounds according to general formula (I) which are analogues of epoxymetabolites produced by cytochrome P450 (CYP) enzymes from omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for the treatment or prevention of conditions and diseases associated with inflammation, proliferation, hypertension, coagulation, immune function, pathologic angiogenesis, heart failure and cardiac arrhythmias.

CYP-eicosanoid derivatives

The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1, 2 and 3 for use in therapy and/or diagnosis of autoimmune diseases, wherein the autoimmune disease is cardiomyopathy, dilated cardiomyopathy (DCM), peripartum cardiomyopathy (PPCM), idiopathic cardiomyopathy, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaesophagus, Chagas' neuropathy, benign prostatic hyperplasia, scleroderma, psoriasis, Raynaud syndrome, pre-eclampsia, kidney allograft rejection, myocarditis, glaucoma, hypertension, pulmonary hypertension, malignant hypertension, and/or Alzheimer's disease.

Use of aptamers in therapy and/or diagnosis of autoimmune diseases

The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1, 2 and 3 for use in therapy and/or diagnosis of autoimmune diseases, wherein the autoimmune disease is cardiomyopathy, dilated cardiomyopathy (DCM), peripartum cardiomyopathy (PPCM), idiopathic cardiomyopathy, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaesophagus, Chagas' neuropathy, benign prostatic hyperplasia, scleroderma, psoriasis, Raynaud syndrome, pre-eclamsia, kidney allograft rejection, myocarditis, glaucoma, hypertension, pulmonary hypertension, malignant hypertension, and/or Alzheimer's disease.

A peptide having an EDof less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular &#x3b1;1 loop 2 or &#x3b2;2 loop1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of &#x3b3;-secretase activity, an increased release of &#x3b2;-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the EDvalue is measured by bioassay.

Peptides having binding affinity to an antibody which recognizes an epitope on an &#x3b1;1 loop 2 or &#x3b2;2 loop 1 of an adrenoreceptor

The present invention provides compounds (n-3 PUFA derivatives) of formula (I) that modulate conditions associated with cardiac damage, especially cardiac arrhythmias. 

A peptide having an EDof less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular &#x3b1;1 loop 2 or &#x3b2;2 loop 1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of &#x3b3;-secretase activity, an increased release of &#x3b2;-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the EDvalue is measured by bioassay.

The invention relates to nucleic acid molecules encoding peptides which are directed against autoantibodies associated with cold allergy, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said nucleic acid molecules and peptides for the treatment of circulatory disorders associated with exposure to cold or intolerance to cold, especially cold allergies.

Peptides against autoantibodies causing intolerance to cold and use thereof

Disclosed are peptides of the ATreceptor and their use for eliminating specifically binding, cell-physiologically active, pathological antibodies in preeclampsia and malign hypertension. The peptides may, for example, be used for the diagnosis of preeclampsia. Peptides having the sequence AFHYESQ (SEQ ID NO: 1), AVHYQSN (SEQ ID NO: 2), SHFYQTR (SEQ ID NO: 3), GYYFDTN (SEQ ID NO: 4) or ENTNIT (SEQ ID NO: 5) are preferred.

[object Object]

The invention relates to a method for detecting disease-associated autoantibodies, which recognize extracellular structures of G protein-coupled receptors, and to the use of peptides, which comprise these loops or fragments thereof, for treating autoimmune diseases.

Identification of agonistic autoantibodies

Peptides which bind auto-antibodies being in a causally pathological relationship with dilatative cardiomyopathy are described. The peptides may be bound, for example, to a solid phase. Auto-antibodies can be removed by treating blood of patients suffering from DCM with the peptides according to the invention.

Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (DCM)

Growing community of inventors

Berlin, Germany

Gerd Wallukat